AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study OverviewAstraZeneca is running a Phase IIb study titled “A Phase ...

WEDNESDAY, Dec. 10, 2025 (HealthDay News) — Taking opioids may make some patients more likely to develop a dangerous infection, new research suggests. The infection is called Clostridioides difficile, ...

In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Nitazoxanide is a new thiazolide antiparasitic agent that has excellent activity in treating both interstitial protozoal and helminthic infections. [3,17] Pharmacokinetic studies in humans have shown ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home ...

Vowst (fecal microbiota spores, live-brpk) can cause side effects that range from mild to serious. More common side effects include tiredness and constipation. If side effects from Vowst become ...

Vowst (fecal microbiota spores, live-brpk) is a brand-name oral capsule that’s prescribed to help prevent Clostridioides difficile (C. diff) infection returning after antibiotic treatment in certain ...

Dear Doctors: I was sick for months with debilitating pain, extreme weight loss, fatigue and loss of appetite. I was diagnosed with C. diff related to an abdominal surgery. I’m being treated with ...

St. Louis-based Washington University School of Medicine researchers found that fidaxomicin, a treatment for Clostridioides difficile infection, has increased in use but “remains underutilized.” The ...